Literature DB >> 708990

The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-DOPA to rats.

J F Deakin, A R Green.   

Abstract

1 The putative 5-hydroxytryptamine (5-HT) receptor blocking drugs methysergide (10 mg/kg) and methergoline (5 mg/kg) were found to abolish some components of the hyperactivity syndrome, including head weaving and forepaw treading, which follow administration to rats of tranylcypromine (20 mg/kg) and L-tryptophan (100 mg/kg). Hyperactivity and hyper-reactivity were potentiated with a resultant increase in automated locomotor activity counts. In contrast (-)-propranolol (20 mg/kg) inhibited all features of the syndrome. The same results were obtained with these drugs when the behaviour was elicited by p-chloroamphetamine (10 mg/kg) or by tranylcypromine and tryptamine (10 mg/kg). 2 Methysergide and methergoline had similar effects on the syndrome produced by tranylcypromine and L-DOPA (50 mg/kg) whereas propranolol was without effect. 3 None of the putative 5-HT receptor antagonists affected brain 5-HT turnover as assessed by rate of accumulation of 5-HT following monoamine oxidase inhibition with tranylcypromine. 4 Microinjections of 5,7-dihydroxytryptamine into the spinal cord resulted in a 70% fall in cord 5-HT concentrations without an effect on brain 5-HT concentrations. The behavioural response to the putative 5-HT receptor agonist, 5-methoxy N,N-dimethyltryptamine (2 mg/kg), was potentiated in these animals suggesting that 5-HT receptors become supersensitive on denervation, and that some components of the behavioural syndrome are mediated by spinal cord 5-HT receptors. 5 Pretreatment with alpha-methyl p-tyrosine (2 X 200 mg/kg) delayed the onset of all components of the behaviour elicited by tranylcypromine/L-tryptophan by 60 min, indicating an involvement of catecholamines in the syndrome. 6 p-Chloroamphetamine-induced 5-HT depletion had no effect on any component of the tranylcypromine-L-DOPA behaviour.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 708990      PMCID: PMC1668312          DOI: 10.1111/j.1476-5381.1978.tb17290.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  Direct evidence for an interaction of beta-adrenergic blockers with the 5-HT receptor.

Authors: 
Journal:  Nature       Date:  1977-05-19       Impact factor: 49.962

2.  Blockade of 5-hydroxytryptamine receptors in the central nervous system by beta-adrenoceptor antagonists.

Authors:  M Weinstock; C Weiss; S Gitter
Journal:  Neuropharmacology       Date:  1977-04       Impact factor: 5.250

3.  Behavioral effects and brain amine content in rats.

Authors:  S M HESS; W DOEPFNER
Journal:  Arch Int Pharmacodyn Ther       Date:  1961-11-01

4.  Postsynaptic serotonin-sensitive adenylate cyclase in the central nervous system. II. Comparison with dopamine- and isoproterenol-sensitive adenylate cyclases in rat brain.

Authors:  A Enjalbert; M Hamon; S Bourgoin; J Bockaert
Journal:  Mol Pharmacol       Date:  1978-01       Impact factor: 4.436

Review 5.  Serotonin receptors in the brain.

Authors:  H J Haigler; G K Aghajanian
Journal:  Fed Proc       Date:  1977-07

6.  Role of tryptaminergic mechanisms in the elements of the behavioural syndrome evoked by tryptophan and a monoamine oxidase inhibitor [proceedings].

Authors:  T J Crow; J F Deakin
Journal:  Br J Pharmacol       Date:  1977-03       Impact factor: 8.739

Review 7.  An animal behavior model for studying central serotonergic synapses.

Authors:  B L Jacobs
Journal:  Life Sci       Date:  1976-09-15       Impact factor: 5.037

8.  Evidence for the functional interaction of two central neurotransmitters.

Authors:  B L Jacobs
Journal:  Psychopharmacologia       Date:  1974

9.  Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan.

Authors:  D G Grahame-Smith
Journal:  J Neurochem       Date:  1971-06       Impact factor: 5.372

10.  Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by L-tryptophan or 5-methoxy-N,N-dimethyltryptamine in rats treated with a monoamine oxidase inhibitor.

Authors:  D G Grahame-Smith
Journal:  Br J Pharmacol       Date:  1971-12       Impact factor: 8.739

View more
  39 in total

1.  Regulation of opioid gene expression in the rat brainstem by 3,4-methylenedioxymethamphetamine (MDMA): role of serotonin and involvement of CREB and ERK cascade.

Authors:  Manuela Di Benedetto; Sussy del Carmen Bastías Candia; Claudio D'Addario; Elena Elettra Porticella; Chiara Cavina; Sanzio Candeletti; Patrizia Romualdi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-12-23       Impact factor: 3.000

Review 2.  Neuropharmacologic correlates of deglutition: lessons from fictive swallowing.

Authors:  D Bieger
Journal:  Dysphagia       Date:  1991       Impact factor: 3.438

3.  The effects of monoamine oxidase inhibitors on the ejaculatory response induced by 5-methoxy-N,N-dimethyltryptamine in the rat.

Authors:  L Rényi
Journal:  Br J Pharmacol       Date:  1986-08       Impact factor: 8.739

4.  5-Hydroxytryptamine release in vivo from a cytoplasmic pool: studies on the 5-HT behavioural syndrome in reserpinized rats.

Authors:  D M Kuhn; W A Wolf; M B Youdim
Journal:  Br J Pharmacol       Date:  1985-01       Impact factor: 8.739

5.  Relationship between extracellular 5-hydroxytryptamine and behaviour following monoamine oxidase inhibition and L-tryptophan.

Authors:  A J Sleight; C A Marsden; K F Martin; M G Palfreyman
Journal:  Br J Pharmacol       Date:  1988-02       Impact factor: 8.739

6.  5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine.

Authors:  M I Colado; T K Murray; A R Green
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

7.  beta-Adrenoceptor agonists enhance 5-hydroxytryptamine-mediated behavioural responses.

Authors:  P J Cowen; D G Grahame-Smith; A R Green; D J Heal
Journal:  Br J Pharmacol       Date:  1982-06       Impact factor: 8.739

8.  Reduced brain serotonergic activity after repeated treatment with beta-adrenoceptor antagonists.

Authors:  H Hallberg; O Almgren; T H Svensson
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

9.  Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline.

Authors:  Z Speiser; T Fine; L Litinetsky; S Eliash; E Blaugrund; S Cohen
Journal:  J Neural Transm (Vienna)       Date:  2007-09-07       Impact factor: 3.575

10.  Effects of 8-OHDPAT and 5-HT1A antagonists WAY100135 and WAY100635, on guinea-pig behaviour and dorsal raphe 5-HT neurone firing.

Authors:  M K Mundey; A Fletcher; C A Marsden
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.